Regent Peak Wealth Advisors LLC Purchases 74 Shares of Zoetis Inc. (NYSE:ZTS)

Regent Peak Wealth Advisors LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 6.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,254 shares of the company’s stock after purchasing an additional 74 shares during the period. Regent Peak Wealth Advisors LLC’s holdings in Zoetis were worth $245,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in ZTS. Sarasin & Partners LLP raised its stake in Zoetis by 546.3% in the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after acquiring an additional 1,904,899 shares during the period. Swedbank AB bought a new stake in shares of Zoetis in the first quarter valued at approximately $210,815,000. Marshall Wace LLP lifted its stake in shares of Zoetis by 7,608.6% during the 2nd quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock valued at $144,874,000 after buying an additional 824,843 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Zoetis by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock worth $6,895,235,000 after buying an additional 414,605 shares during the period. Finally, Canada Pension Plan Investment Board grew its stake in Zoetis by 178.2% in the 1st quarter. Canada Pension Plan Investment Board now owns 639,352 shares of the company’s stock valued at $108,185,000 after buying an additional 409,522 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

NYSE ZTS traded up $1.71 on Wednesday, reaching $194.10. 674,405 shares of the company’s stock traded hands, compared to its average volume of 2,530,907. The stock has a market cap of $87.94 billion, a PE ratio of 37.64, a P/E/G ratio of 2.99 and a beta of 0.89. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The stock has a 50-day simple moving average of $188.57 and a 200 day simple moving average of $176.58. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.41 EPS. As a group, research analysts predict that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 33.86%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ZTS. Piper Sandler increased their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus upped their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.